Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

NCT04978597 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

410

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson

Interventions

DRUG: Opicapone 50 mg
DRUG: Placebo

Sponsor

Bial - Portela C S.A.